Ginkgo Bioworks Holdings에 대한 매도 수량은 투자자에게 Ginkgo Bioworks Holdings의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Ginkgo Bioworks Holdings (NYSE:DNA) 주식, 공매도 수량 보고

Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering and BiosecurityThe majority of revenue in the company comes from the Biosecurity segment, which charges fees for data analytics and services.

Equities

News

Markets

ETFs

ACHR

ARKK

AVAV

BLDE

NTLA

TDOC

TSLA

VERV

수요일에 캐시 우드가 이끄는 아크 인베스트(Ark Invest)는 이 회사의 인상적인 2분기 납품 실적에 힘입은 최근 상승세에도 불구하고 테슬라(NASDAQ:TSLA)의 상당 수의 주식을 매각하여 주목할만한 움직임을 보였다.

아크 인베스트가 예상을 넘는 2분기 배송 실적에도 $3.25백만 규모 테슬라 주식 매도 추가

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

ARKW

COIN

ROKU

수요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 변동성이 큰 시장 속에서 로쿠(NASDAQ:ROKU)와 코인베이스 글로벌(NASDAQ:COIN)에서 상당한 거래를 했다. 이러한 눈에 띄는 거래는 아크의 다양한 ETF가 수행한 일련의 거래의 일부였다.
로쿠 거래

아크 인베스트는 로쿠 $730만의 주식을 매수, 비트코인 하락에 코인베이스 주식을 매각

ARCT

ARKQ

MKFG

NVDA

2024년 6월 25일 화요일, 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 상당한 시장 변동성 속에서 엔비디아(NASDAQ:NVDA)와 로쿠(NASDAQ:ROKU)에서 상당한 거래를 했다. 이러한 거래는 아크의 다양한 ETF가 이행한 일련의 거래의 일부였다.

아크 인베스트는 주가 반등 속에 엔비디아 주식에서 $430만 매도, 로쿠 주식을 매수

Ginkgo Bioworks Holdings, Inc. Class A Common Stock

Ginkgo Bioworks Holdings Inc

Metaverse Dualchain Network Architecture

DeNA Co Ltd

DNAPRINT GENOMICS INC by DNAPrint Genomics, Inc.

DNA Print Genomics Inc

DNA Brands Inc

US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) reported quarterly earnings of $0.69 per share which beat the analyst consensus estimate of $0.68 by 1.47 percent. This is a 11.29 percent increase over earnings of $0.62 per share from the same period last year. The company reported quarterly sales of $168.033 million which beat the analyst consensus estimate of $164.381 million by 2.22 percent. This is a 12.02 percent increase over sales of $150.007 million the same period last year.

Earnings

Earnings Beats

USPH

US Physical Therapy Q3 2024 Adj. EPS $0.69 Beats $0.68 Estimate, Sales $168.033M Beat $164.381M Estimate

Guidance

LUMN

Lumen Technologies Continues To Expect FY24 Adjusted EBITDA Of $3.9B - $4.0B, Net Cash Interest Of $1.15B - $1.25B

Gulfport Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPOR#NYSE">GPOR</a>) reported quarterly earnings of $3.42 per share which beat the analyst consensus estimate of $2.93 by 16.72 percent. The company reported quarterly sales of $253.912 million which missed the analyst consensus estimate of $278.980 million by 8.99 percent. This is a 11.73 percent increase over sales of $227.250 million the same period last year.

Earnings Misses

GPOR

Gulfport Energy Q3 2024 Adj. EPS $3.42 Beats $2.93 Estimate, Sales $253.912M Miss $278.980M Estimate

Eos Energy Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) lowers FY2024 sales outlook from $60.00 million-90.00 million to $15.00 million.

EOSE

Eos Energy Enterprises Lowers FY2024 Sales Guidance from $60.00M-90.00M to $15.00M  VS Est. 62.33M

Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) reported quarterly earnings of $0.90 per share which beat the analyst consensus estimate of $0.21 by 328.57 percent. This is a 221.43 percent increase over earnings of $0.28 per share from the same period last year. The company reported quarterly sales of $110.71 million which beat the analyst consensus estimate of $76.11 million by 45.46 percent. This is a 964.81 percent increase over sales of $10.40 million the same period last year.

MGNX

Macrogenics Q3 EPS $0.90 Beats $0.21 Estimate, Sales $110.71M Beat $76.11M Estimate

Forrester Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORR#NASDAQ">FORR</a>) reported quarterly earnings of $0.29 per share which missed the analyst consensus estimate of $0.34 by 14.71 percent. This is a 34.09 percent decrease over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $102.527 million which beat the analyst consensus estimate of $101.944 million by 0.57 percent. This is a 9.61 percent decrease over sales of $113.431 million the same period last year.

FORR

Forrester Res Q3 2024 Adj. EPS $0.29 Misses $0.34 Estimate, Sales $102.527M Beat $101.944M Estimate

B&G Foods Sees FY24 Net Sales $1.920B-$1.950B Vs $1.951B Est.; Adj. Diluted EPS $0.67-$0.77

Cytek Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.02) by 150 percent. The company reported quarterly sales of $51.500 million which beat the analyst consensus estimate of $50.696 million by 1.59 percent. This is a 7.29 percent increase over sales of $48.000 million the same period last year.

CTKB

Cytek Biosciences Q3 2024 GAAP EPS $0.01 Beats $(0.02) Estimate, Sales $51.500M Beat $50.696M Estimate

Full year fiscal 2025 guidance:2
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="2" rowspan="1">Current</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GAAP</td>
<td colspan="1" rowspan="1">Low</td>
<td colspan="1" rowspan="1">High</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">$2,369</td>
<td colspan="1" rowspan="1">$2,391</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operating margin3</td>
<td colspan="1" rowspan="1">23.0&nbsp;%</td>
<td colspan="1" rowspan="1">23.2&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">EPS</td>
<td colspan="1" rowspan="1">$5.78</td>
<td colspan="1" rowspan="1">$5.87</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP4</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted revenue</td>
<td colspan="1" rowspan="1">$2,353</td>
<td colspan="1" rowspan="1">$2,375</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted operating margin</td>
<td colspan="1" rowspan="1">22.7&nbsp;%</td>
<td colspan="1" rowspan="1">22.8&nbsp;%</td>
</tr>
</tbody>
</table>
</figure>
<a href="https://mma.prnewswire.com/media/2549531/JKHY_Key_Call_Outs___Q1_FY25.html"><img src="https://mma.prnewswire.com/media/2549531/JKHY_Key_Call_Outs___Q1_FY25.jpg" alt="Key Call-Outs" /></a>

JKHY

Jack Henry & Associates Sees FY25 EPS $5.78-$5.87 Vs $5.83 Est.; Revenue $2.353B-$2.375B Vs $2.37B Est.

Latham Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) narrows FY2024 sales outlook from $495.00 million-525.00 million to $500.00 million-510.00 million.

SWIM

Latham Group Narrows FY2024 Sales Guidance from $495.00M-525.00M to $500.00M-510.00M  VS Est. 512.39M

Meme cryptocurrency Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) has experienced a surge in trading volume and price activity leading up to the <a href="https://www.benzinga.com/topic/2024-election">2024 presidential election.</a>
A Benzinga poll asks readers to choose whether a victory by Donald Trump or Kamala Harris in the election could have a more positive impact on Dogecoin in 2025.
What Happened: Dogecoin is up 12% to $0.1761 on Tuesday, with the meme cryptocurrency seeing increased activity likely related to the 2024 election <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41734897/elon-musks-doge-department-mention-gives-dogecoin-boost-to-top-of-daily-gainers-memecoin-s">and positive mentions </a>of the Department of Government Efficiency, or D.O.G.E. for short, by Elon Musk.
Musk is expected to join the Trump administration if the former president wins the 2024 election. In this role, Musk would seek to cut government inefficiencies and unnecessary departments, a role labeled under the D.O.G.E.
The Tesla CEO and billionaire mentioned D.O.G.E. during his<a href="https://www.benzinga.com/general/education/24/11/41752565/if-you-invested-1-000-in-tesla-stock-the-first-time-elon-musk-was-on-the-joe-rogan-podcast-here"> most recent appearance</a> Monday on "The Joe Rogan Experience" podcast, which is likely contributing to Dogecoin's strong movement on Tuesday.
"For Dogecoin's future in 2025, who would be the better president: Kamala Harris or Donald Trump?" Benzinga recently asked.
The results were:
<ul>
<li>Donald Trump: 72%</li>
<li>Kamala Harris: 28%</li>
</ul>
The Benzinga poll found that respondents believe Trump would be more favorable for the future of Dogecoin, which may not come as a surprise given the former president&#8217;s reputation as a more pro-crypto leader.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent110524">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
What's Next: Trump, who previously <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38749745/if-you-invested-1-000-in-bitcoin-when-donald-trump-said-the-cryptos-value-was-based-on-thi">spoke out against Bitcoin, </a>reversed course and has appealed to cryptocurrency investors ahead of the 2024 election.
If Trump wins the 2024 election, cryptocurrency investors expect the price of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and other cryptocurrencies to rise with a more crypto-friendly government in place and the likelihood that SEC Chair Gary Gensler will be replaced.
While Harris has not been as vocal on cryptocurrency as Trump, there is belief that she <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41322645/mark-cuban-defends-kamala-harris-crypto-knowledge-appears-to-take-dig-at-trump-for-selling">could look to advance</a> the sector forward if she wins the election.
Either way, Dogecoin could see high volatility during the week as the 2024 election outcome is expected to take some time to make official.
With a price of $0.1761 on Tuesday, Dogecoin is nearing its one-month high of $0.1792.
Over the last 52 weeks, Dogecoin has traded between $0.07028 and $0.2266. Dogecoin hit all-time highs of $0.7376 back in May 2021.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41410605/if-you-invested-100-in-dogecoin-when-elon-musk-first-tweeted-about-the-meme-crypto-heres-h">If You Invested $100 In Dogecoin When Elon Musk First Tweeted About The Meme Crypto, Here&#8217;s How Much You&#8217;d Have Today</a></li>
</ul>
The study was conducted by Benzinga from Nov. 4 through Nov. 5, 2024, and included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 134 adults.
Image created with Shutterstock and Midjourney.

Exclusives

$DOGE

Dogecoin Jumps On Election Day: Poll Asks If Trump Or Harris Victory Will Spark 2025 Rally

WIIM

Devon Energy shares are trading higher following a Q3 earnings beat.

Ashford Hospitality Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHT#NYSE">AHT</a>) reported quarterly AFFO of $(1.71) per share which missed the analyst consensus estimate of $(0.97) by 76.29 percent. This is a 311.11 percent decrease over earnings of $0.81 per share from the same period last year. The company reported quarterly sales of $276.60 million which beat the analyst consensus estimate of $268.97 million by 2.84 percent. This is a 19.36 percent decrease over sales of $343.01 million the same period last year.

Ashford Hospitality Trust Q3 2024 AFFO $(1.71) Misses $(0.97) Estimate, Sales $276.60M Beat $268.97M Estimate

Jack Henry &amp; Associates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JKHY#NASDAQ">JKHY</a>) reported quarterly earnings of $1.63 per share which beat the analyst consensus estimate of $1.61 by 1.24 percent. This is a 17.27 percent increase over earnings of $1.39 per share from the same period last year. The company reported quarterly sales of $600.98 million which beat the analyst consensus estimate of $600.11 million by 0.15 percent. This is a 5.18 percent increase over sales of $571.37 million the same period last year.

Jack Henry & Associates Q1 EPS $1.63 Beats $1.61 Estimate, Sales $600.98M Beat $600.11M Estimate

B&amp;G Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGS#NYSE">BGS</a>) reported quarterly earnings of $0.13 per share which missed the analyst consensus estimate of $0.20 by 35 percent. The company reported quarterly sales of $461.10 million which missed the analyst consensus estimate of $473.12 million by 2.54 percent. This is a 8.28 percent decrease over sales of $502.73 million the same period last year.

B&G Foods Q3 2024 Adj EPS $0.13 Misses $0.20 Estimate, Sales $461.10M Miss $473.12M Estimate

NHI is updating its 2024 annual guidance range which includes the following:
NAREIT FFO per diluted common share to a range of $4.39 - $4.41 from $4.50 - $4.54;
Normalized FFO per diluted common share to a range of $4.43 - $4.44 from $4.52 - $4.56; and
Normalized FAD to a range of $201.8 million - $202.5 million from $200.1 million - $201.8 million;
NAREIT FFO and Normalized FFO revised guidance is primarily due to lower cash lease revenue and interest income assumptions, and a $3.6 million non-cash increase to the credit loss reserve attributable to Senior Living Management. This was partially offset by acquisitions closed since August 2024 funded primarily with forward equity proceeds;
Normalized FAD revised guidance is primarily due to acquisitions closed since August 2024 offset by lower cash lease revenue and interest income assumptions attributable to Senior Living Management.

National Health Investors Updates FY24 NAREIT FFO Per Diluted Share From $4.50-$4.54 To $4.39-$4.41; Normalized FFO Per Diluted Share From $4.52-$4.56 To $4.43-$4.44

Aviat Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVNW#NASDAQ">AVNW</a>) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.03) by 2800 percent. This is a 245 percent decrease over earnings of $0.60 per share from the same period last year. The company reported quarterly sales of $88.43 million which missed the analyst consensus estimate of $94.21 million by 6.14 percent. This is a 1.75 percent increase over sales of $86.91 million the same period last year.

AVNW

Aviat Networks Q1 Adj $(0.87) Misses $(0.03) Estimate, Sales $88.43M Miss $94.21M Estimate

Vtex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTEX#NYSE">VTEX</a>) lowers FY2024 sales outlook from $231.00 million-235.00 million to $230.00 million-232.00 million.

VTEX

Vtex Lowers FY2024 Sales Guidance from $231.00M-235.00M to $230.00M-232.00M.

MASI

Masimo Sees Q4 Revenue $581M-$611M; Q4 Adj. EPS $1.35-$1.50

Vtex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTEX#NYSE">VTEX</a>) sees Q4 sales of $64.800 million-66.800 million vs $67.57 million estimate.

Vtex Sees Q4 Sales $64.800M-66.800M vs $67.57M Est.

Ginkgo Bioworks Holdings (DNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mark Mas...

Ginkgo Bioworks Holdings: Sell Rating Affirmed with Revised Valuation and Price Target

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ginkgo Bioworks Holdings (DNA – Research Report), BioMarin Pharma...

Analysts Offer Insights on Healthcare Companies: Ginkgo Bioworks Holdings (DNA), BioMarin Pharmaceutical (BMRN) and Tactile Systems Technology (TCMD)

Stocks hitting all-time highs: JPM, KO, LMT, UNH, and more

Ginkgo Bioworks regains compliance with NYSE minimum bid price requirement

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2024 Update

Brendan Smith, an analyst from TD Cowen, maintained the Buy rating on Ginkgo Bioworks Holdings (DNA – Research Report). The associated price target...

Ginkgo Bioworks Holdings: A Buy Rating on Strategic AI Advancements and Market Expansion

The Top Five short crowded stocks in each U.S. sector

Guggenheim SMid Cap Value Fund Q2 2024 Commentary

Interest Rate Regimes And ARKG: Underperformance Explained

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bausch + Lomb Corporation (BLCO – Research Report)...

Analysts Offer Insights on Healthcare Companies: Bausch + Lomb Corporation (BLCO), Ginkgo Bioworks Holdings (DNA) and Eli Lilly & Co (LLY)

AAPL

ACHC

ADBE

ADPT

AMKR

AMZN

APLE

ARKG

ASIX

AVGO

BBIO

BEPC

BIRD

BLCO

BMBL

BMRN

CABO

CBRL

CDNA

CERT

CMTL

COHR

CRSP

DASH

DDOG

DLTR

ECVT

ENOV

EVRG

EVTC

EWTX

EXAS

FANG

FDMT

FERG

IART

INBX

INST

IONS

LBPH

LDOS

MGPI

MNTK

MSFT

NAMS

NAPA

NEWT

NFLX

NTST

NXDT

ORIC

PACB

PDCO

PEPG

PHVS

REXR

ROIV

RPRX

RXRX

SDGR

SIRI

TCMD

TMUS

TROW

TRVI

TTWO

TWST

ULCC

VKTX

VTLE

WDAY

Press Releases

Ginkgo Bioworks Reports Second Quarter 2024 Financial Results

Ginkgo Bioworks Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare Conference

Legal

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Ginkgo Bioworks Holdings, Inc. Common Stock - DNA

Ginkgo Regains Compliance with NYSE Minimum Bid Price Requirement

Ginkgo Bioworks Launches New Protein LLM and Model API Built on Google Cloud Technology

Ginkgo Bioworks Launches Ginkgo Datapoints to Transform AI Model Training in Biology

Pomerantz LLP Announces that this is a Reminder of a Proposed Class Action Settlement on Behalf of Purchasers of Ginkgo Bioworks Holdings, Inc. Common Stock - DNA

NOVUS Leverages Ginkgo Bioworks to Develop Innovative Feed Additives for Animal Agriculture

Comments

Ginkgo Bioworks Holdings

매도 수량

Ginkgo Bioworks Holdings (NYSE:DNA) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌